Faculty
Doug Adkins.jpg

Douglas R. Adkins, MD

Professor
Department of Medicine
Oncology Division
Medical Oncology

Clinical Interests

  • Head and neck cancer
  • Sarcoma
  • Thyroid cancer

Contact

  • 314-747-8475 (tel)
  • 314-362-7086 (fax)
  • 11th Floor Mid-Campus Center (office)
  • Division of Oncology
    Campus Box 8056
    Washington University Medical School
    660 South Euclid Avenue
    St. Louis, MO 63110

Research

Areas of Clinical Research Interest

  • Evaluation of the addition of nanoparticle-bound paclitaxel and EGFR inhibitors to induction chemotherapy in patients with SCCHN
  • Evaluation of CDK 4/6 inhibitirs in patients with SCCHN
  • Evaluation of VEGFR inhibitors in patients with SCCHN
  • Evaluation of targeted agents in the treatment of medullary, differentiated and anaplastic thyroid cancers

Current Research Projects

SCCHN

  • Determination of the primary tumor site response and survival outcomes of four novel induction chemotherapy regimens, APF-C (cisplatin, 5-FU, cetuximab, and abraxane), APF, AP, and A in patients with locally advanced SCCHN
  • Determine the maximum tolerable dose of pazopanib suspension when combined with fixed dose cetuximab in patients with incurable SCCHN
  • Determine the maximum tolerable dose of PD0332991 when administered with cetuximab in patients with incurable SCCHN and then determine the efficacy of PD0332991 in combination with cetuximab in incurable HPV-unrelated SCCHN
  • Participation in cooperative group (RTOG, ECOG, SWOG, P2C), pharmaceutical and multi-institutional investigator initiated clinical trials in SCCHN: ECOG 1302 and 1305, Paradigm, AVIT, ARQ 501, Zactima, Imclone Lorhan Registry trials, Panitumumab, E7050, Temsirolimus, ARQ 197, VTX-2337, GC4419, SGX942, BYL719, and BKM120

Sarcoma

  • Participation in cooperative group (Phase II Mayo Consortium, SWOG) and pharmaceutical clinical trials in sarcoma: STA-4783 (Synta), Sorafenib (SWOG), Glufosphamide (Threshold), CCI-779 (P2C), SAHA (P2C), IMC A12 (Imclone), Deforolimus (Ariad) Paliphosphamide (Ziopharm), Eribulin (Eisai), Trabectadin (J&J), TH-302 (Threshold)

Thyroid Cancer

  • Participation in cooperative group (Phase II Mayo Consortium) and pharmaceutical clinical trials in thyroid cancer: 17-AAG (P2C), Zactima, Sorafenib, XL184 (Exelixis), CS-7017 (Daiichi Sankyo Pharma), Pazopanib (P2C), Cediranib/Lenalidomide (P2C)